Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Learn more about PCSK9 Inhibition and lipid control in this open-access article from ECR Journal. PCSK9 Inhibition: The Big Step Forward in Lipid Control.
Conclusions/Relevance: Thus far, randomised controlled trials have shown that subcutaneous fully human monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, and PCSK9 silencing with inclisiran result in drastic reductions in LDL cholesterol. Additionally, several novel strategies to target PCSK9 are in development, including oral...
Share
Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37464942/
Lipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk...
Relevance: The purpose of this review is to describe current recommendations for screening and managing elevated Lp(a), describe the effects of currently available lipid-lowering therapies on Lp(a) levels, and provide insight into emerging therapies targeting Lp(a).
Share
Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37453072/
Our real world findings suggest that in CIED HF patients, those with SGLT2i had a pronounced reduction in ATA burden and all-cause mortality when compared with those not on SGLT2i.
Conclusion: Our real world findings suggest that in CIED HF patients, those with SGLT2i had a pronounced reduction in ATA burden and all-cause mortality when compared with those not on SGLT2i.
Share
The German CaRe high registry for familial hypercholesterolemia - Sex differences, treatment strategies, and target value attainment
Source : https://www.sciencedirect.com/science/article/pii/S2667089523000093?via=ihub
Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, an...
Conclusions: FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be associated with increased treatment intensity. Achieving the LDL-C goals of the 2019 ESC/EAS dyslipidemia guidelines remains challenging if pre-treatment LDL-C is...
Share
-
Lipid Management Connect2yrKey Points • Source: Atherosclerosis Plus • Conclusion: “FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be Show More
Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results
Source : https://www.sciencedirect.com/science/article/pii/S0214916823000517?via=ihub
Las enfermedades cardiovasculares (ECV) representan la principal causa de muerte y discapacidad en todo el mundo, siendo el colesterol elevado uno de ...
Conclusions: Evolocumab was associated with reductions in LDL-C levels, with a relative decrease of 63.9% within the first 3 months of treatment. Low rates of interruptions due to adverse events and adequate medication persistence was reported.
Share